Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Status:
Terminated
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This is a clinical trial of orally administered Ruxolitinib (INCB018424) in patients whose
disease has progressed following 1 prior chemotherapy regimen (not including anti-androgens
or ketoconazole) for metastatic, androgen-independent prostate cancer.